Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leiner

This article was originally published in The Tan Sheet

Executive Summary

Begins shipping in March Central Vite Plus under its Your Life dietary supplement control brand. Central Vite Plus -- which will be available in a 130-count bottle for $8.99 suggested retail and a 300-count club size for $14.99 suggested retail -- contains 200% of the RDA for antioxidants vitamin E (60 IU), vitamin C (120 mg) and beta carotene (10,000 IU). Leiner already markets Central Vite, which is similar to Lederle's Centrum multivitamin. Leiner launched in February three additions to its Pharmacist Formula OTC control brand that are also available to private-label customers - - Children's Non-Aspirin Grape Suspension Liquid and Infants' Non- Aspirin Grape Suspension Drops, both modeled after Tylenol suspensions, and a Decongestant Nasal Inhaler similar to P&G's Vicks Decongestant Inhaler

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS082638

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel